Copyright Reports & Markets. All rights reserved.

Global Chronic Granulomatous Disease (CGD) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Chronic Granulomatous Disease (CGD) Treatment
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Chronic Granulomatous Disease (CGD) Treatment by Type
    • 1.3.1 Overview: Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Chronic Granulomatous Disease (CGD) Treatment Consumption Value Market Share by Type in 2022
    • 1.3.3 X-Linked Chronic Granulomatous Disease
    • 1.3.4 Autosomal Recessive Chronic Granulomatous Disease
  • 1.4 Global Chronic Granulomatous Disease (CGD) Treatment Market by Application
    • 1.4.1 Overview: Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Neutrophil Function Tests
    • 1.4.3 Genetic Testing
    • 1.4.4 Prenatal Testing
  • 1.5 Global Chronic Granulomatous Disease (CGD) Treatment Market Size & Forecast
  • 1.6 Global Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast by Region
    • 1.6.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region, (2018-2029)
    • 1.6.3 North America Chronic Granulomatous Disease (CGD) Treatment Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size and Prospect (2018-2029)
    • 1.6.6 South America Chronic Granulomatous Disease (CGD) Treatment Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Chronic Granulomatous Disease (CGD) Treatment Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Clinigen Group plc
    • 2.1.1 Clinigen Group plc Details
    • 2.1.2 Clinigen Group plc Major Business
    • 2.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.1.4 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Clinigen Group plc Recent Developments and Future Plans
  • 2.2 Orchard Therapeutics plc2032
    • 2.2.1 Orchard Therapeutics plc2032 Details
    • 2.2.2 Orchard Therapeutics plc2032 Major Business
    • 2.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.2.4 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Orchard Therapeutics plc2032 Recent Developments and Future Plans
  • 2.3 Horizon Therapeutics plc
    • 2.3.1 Horizon Therapeutics plc Details
    • 2.3.2 Horizon Therapeutics plc Major Business
    • 2.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.3.4 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Horizon Therapeutics plc Recent Developments and Future Plans
  • 2.4 ViroMed. Co. Ltd
    • 2.4.1 ViroMed. Co. Ltd Details
    • 2.4.2 ViroMed. Co. Ltd Major Business
    • 2.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.4.4 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 ViroMed. Co. Ltd Recent Developments and Future Plans
  • 2.5 Bellicum Pharmaceuticals, Inc
    • 2.5.1 Bellicum Pharmaceuticals, Inc Details
    • 2.5.2 Bellicum Pharmaceuticals, Inc Major Business
    • 2.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.5.4 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Bellicum Pharmaceuticals, Inc Recent Developments and Future Plans
  • 2.6 Pfizer Inc
    • 2.6.1 Pfizer Inc Details
    • 2.6.2 Pfizer Inc Major Business
    • 2.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.6.4 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Pfizer Inc Recent Developments and Future Plans
  • 2.7 Hoffmann-La Roche Ltd
    • 2.7.1 Hoffmann-La Roche Ltd Details
    • 2.7.2 Hoffmann-La Roche Ltd Major Business
    • 2.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.7.4 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Hoffmann-La Roche Ltd Recent Developments and Future Plans
  • 2.8 Novartis AG
    • 2.8.1 Novartis AG Details
    • 2.8.2 Novartis AG Major Business
    • 2.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.8.4 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Novartis AG Recent Developments and Future Plans
  • 2.9 Lonza
    • 2.9.1 Lonza Details
    • 2.9.2 Lonza Major Business
    • 2.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.9.4 Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Lonza Recent Developments and Future Plans
  • 2.10 GlaxoSmithKline plc
    • 2.10.1 GlaxoSmithKline plc Details
    • 2.10.2 GlaxoSmithKline plc Major Business
    • 2.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.10.4 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 GlaxoSmithKline plc Recent Developments and Future Plans
  • 2.11 Eli Lilly and Company
    • 2.11.1 Eli Lilly and Company Details
    • 2.11.2 Eli Lilly and Company Major Business
    • 2.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.11.4 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.12 Johnson & Johnson Services, Inc
    • 2.12.1 Johnson & Johnson Services, Inc Details
    • 2.12.2 Johnson & Johnson Services, Inc Major Business
    • 2.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.12.4 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Johnson & Johnson Services, Inc Recent Developments and Future Plans
  • 2.13 Merck KGaA
    • 2.13.1 Merck KGaA Details
    • 2.13.2 Merck KGaA Major Business
    • 2.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product and Solutions
    • 2.13.4 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Merck KGaA Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Chronic Granulomatous Disease (CGD) Treatment Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Chronic Granulomatous Disease (CGD) Treatment by Company Revenue
    • 3.2.2 Top 3 Chronic Granulomatous Disease (CGD) Treatment Players Market Share in 2022
    • 3.2.3 Top 6 Chronic Granulomatous Disease (CGD) Treatment Players Market Share in 2022
  • 3.3 Chronic Granulomatous Disease (CGD) Treatment Market: Overall Company Footprint Analysis
    • 3.3.1 Chronic Granulomatous Disease (CGD) Treatment Market: Region Footprint
    • 3.3.2 Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Type Footprint
    • 3.3.3 Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Chronic Granulomatous Disease (CGD) Treatment Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Chronic Granulomatous Disease (CGD) Treatment Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Type (2018-2029)
  • 6.2 North America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Application (2018-2029)
  • 6.3 North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country
    • 6.3.1 North America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Country (2018-2029)
    • 6.3.2 United States Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Type (2018-2029)
  • 7.2 Europe Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Application (2018-2029)
  • 7.3 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country
    • 7.3.1 Europe Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 7.3.3 France Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region
    • 8.3.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Region (2018-2029)
    • 8.3.2 China Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 8.3.5 India Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Type (2018-2029)
  • 9.2 South America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Application (2018-2029)
  • 9.3 South America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country
    • 9.3.1 South America Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country
    • 10.3.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Chronic Granulomatous Disease (CGD) Treatment Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Chronic Granulomatous Disease (CGD) Treatment Market Drivers
  • 11.2 Chronic Granulomatous Disease (CGD) Treatment Market Restraints
  • 11.3 Chronic Granulomatous Disease (CGD) Treatment Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Chronic Granulomatous Disease (CGD) Treatment Industry Chain
  • 12.2 Chronic Granulomatous Disease (CGD) Treatment Upstream Analysis
  • 12.3 Chronic Granulomatous Disease (CGD) Treatment Midstream Analysis
  • 12.4 Chronic Granulomatous Disease (CGD) Treatment Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Chronic Granulomatous Disease (CGD) Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Chronic Granulomatous Disease (CGD) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Chronic Granulomatous Disease (CGD) Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Chronic Granulomatous Disease (CGD) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Chronic Granulomatous Disease (CGD) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Chronic Granulomatous Disease (CGD) Treatment market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Chronic Granulomatous Disease (CGD) Treatment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Chronic Granulomatous Disease (CGD) Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd and Bellicum Pharmaceuticals, Inc, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Chronic Granulomatous Disease (CGD) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    X-Linked Chronic Granulomatous Disease
    Autosomal Recessive Chronic Granulomatous Disease
    Market segment by Application
    Neutrophil Function Tests
    Genetic Testing
    Prenatal Testing
    Market segment by players, this report covers
    Clinigen Group plc
    Orchard Therapeutics plc2032
    Horizon Therapeutics plc
    ViroMed. Co. Ltd
    Bellicum Pharmaceuticals, Inc
    Pfizer Inc
    Hoffmann-La Roche Ltd
    Novartis AG
    Lonza
    GlaxoSmithKline plc
    Eli Lilly and Company
    Johnson & Johnson Services, Inc
    Merck KGaA
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Chronic Granulomatous Disease (CGD) Treatment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Chronic Granulomatous Disease (CGD) Treatment, with revenue, gross margin and global market share of Chronic Granulomatous Disease (CGD) Treatment from 2018 to 2023.
    Chapter 3, the Chronic Granulomatous Disease (CGD) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Chronic Granulomatous Disease (CGD) Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Chronic Granulomatous Disease (CGD) Treatment.
    Chapter 13, to describe Chronic Granulomatous Disease (CGD) Treatment research findings and conclusion.

    Buy now